Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?

BACKGROUND: Pulmonary arterial hypertension (PAH) has witnessed dramatic treatment advances over the past decade. However, with the exception of epoprostenol, data from short-term randomized controlled trials (RCTs) have not shown a benefit of these drugs on survival. There remains a need to differe...

Descripción completa

Detalles Bibliográficos
Autores principales: Steele, Peter, Strange, Geoff, Wlodarczyk, John, Dalton, Brad, Stewart, Simon, Gabbay, Eli, Keogh, Anne
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841582/
https://www.ncbi.nlm.nih.gov/pubmed/20170553
http://dx.doi.org/10.1186/1471-2261-10-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841582/
https://www.ncbi.nlm.nih.gov/pubmed/20170553
http://dx.doi.org/10.1186/1471-2261-10-9

Ejemplares similares